topic

686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
Maria Jose Costa, Ryan Stafford, Zhiqiang Ku, Jing-Tyan Ma, Krista McCutcheon, Xiaoye Liu, Heyu Chen, Kyu Hong, Tao Huang, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang, X Charlene Liao, An Song

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A411-A412; DOI: 10.1136/jitc-2020-SITC2020.0686
696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo
Bryan Grogan, Reice James, Michelle Ulrich, Shyra Gardai, Ryan Heiser, Reice James

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A418-A419; DOI: 10.1136/jitc-2020-SITC2020.0696
698 Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody
Douglas Hodges, Christina Kochel, Michael Totagrande, Jeffrey Jones, Megan Welch, Bradley Spatola, Shelby Joe, John Corbin, Vanessa Soros, Courtney Beers, Achim Moesta

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A419-A420; DOI: 10.1136/jitc-2020-SITC2020.0698
754 Dysregulation of soluble immune checkpoint proteins in newly – diagnosed early breast cancer patients
Bernardo Rapoport, Helen Steel, Simon Nayler, Teresa Smit, Liezl Heyman, Annette Theron, Nomsa Hlatswayo, Luyanda Kwofie, Carol Ann Benn, Lidia jooste, Ronald Anderson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A452-A453; DOI: 10.1136/jitc-2020-SITC2020.0754
757 Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma
Hsuan-Chen Liu, Dixita Viswanath, Robin Vander Pol, Corrine Chua, Alessandro Grattoni

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A454; DOI: 10.1136/jitc-2020-SITC2020.0757
764 Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet
Pia Aehnlich, Per Thor Straten, Ana Micaela Carnaz Simoes, Signe Skadborg, Gitte Olofsson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A458; DOI: 10.1136/jitc-2020-SITC2020.0764
776 A role for immune checkpoint blockade to enhance T cell-mediated responses in combination with chemotherapy in oesophageal adenocarcinoma
Maria Davern, Joanne Lysaght, Andrew Sheppard, Stephen Maher, Noel Donlon, John Reynolds, Fiona Connell, Conall Hayes, Ross King, Anshul Bhardwaj

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A465-A467; DOI: 10.1136/jitc-2020-SITC2020.0776
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
Jifang Gong, Lin Shen, Zhi Dong, Dan Liu, June Xu, Jing Yang, Yue Yang, Yakun Qi, Jie Men, Paul Kong, Ting Xu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A485-A486; DOI: 10.1136/jitc-2020-SITC2020.0810
819 Targeting vasoactive intestinal peptide receptor signaling: a novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma
Sruthi Ravindranathan, Passang Tenzin, Sanjay Chandrasekaran, Brandon Ware, Mohammad Zaidi, Shuhua Wang, Rohan Dhamsania, Jingru Zhu, Susan Thomas, Anish Majumdar, Gregory Lesinski, Bassel El-rayes, Edmund Waller

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A489-A491; DOI: 10.1136/jitc-2020-SITC2020.0819
80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab
Bo Wei, John Kang, Miho Kibukawa, Gladys Arreaza, Maureen Maguire, Lei Chen, Ping Qiu, Lixin Lang, Deepti Aurora-Garg, Razvan Cristescu, Diane Levitan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A49-A50; DOI: 10.1136/jitc-2020-SITC2020.0080

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages